Quick Answer
Lyell Immunopharma, Inc. reported Shares Outstanding of 21.25 million shares for fiscal year 2025.
Lyell Immunopharma, Inc. Shares Outstanding — Annual History
| Fiscal Year | Shares Outstanding | YoY Change |
|---|---|---|
| 2025 | 21.25M | +44.1% |
| 2024 | 14.74M | -94.2% |
| 2023 | 253.96M | +1.8% |
| 2022 | 249.57M | +2.8% |
| 2021 | 242.74M | +1459.0% |
| 2020 | 15.57M | — |
Quarterly Shares Outstanding
| Quarter Ending | Shares Outstanding | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | 19.29M | -92.5% | +30.1% |
| June 30, 2025 | 14.83M | -94.2% | -95.0% |
| March 31, 2025 | 295.28M | +15.8% | +1902.8% |
| December 31, 2024 | 14.74M | -94.2% | -94.3% |
| September 30, 2024 | 256.56M | +1.9% | +0.2% |
| June 30, 2024 | 255.95M | +2.0% | +0.4% |
| March 31, 2024 | 254.93M | +2.1% | +0.4% |
| December 31, 2023 | 253.96M | +1.8% | +0.8% |
- Lyell Immunopharma, Inc. showed an increase of +44.1% in Shares Outstanding compared to the prior fiscal year.
- Over the 2020–2025 period, Lyell Immunopharma, Inc.’s shares outstanding has grown by 36.5% (from 15.57 million shares to 21.25 million shares).
- The most recent figure is from Lyell Immunopharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: